首頁
Sumitomo Dainippon Pharma Oncology

7月 2026Sumitomo Dainippon Pharm...的市場佔有率分析

sumitomo pharma oncology is a global developer of novel cancer therapeutics. learn about our diverse and purposeful pipeline of targeted therapies.

健康 > 生物技術和製藥

域名sdponcology.com

成立年份2020

僱員201 - 500

年度營收--

Sumitomo Dainippon Pharma Oncology

Sumitomo Dainippon Pharma Oncology（包含公司地區）

sdponcology.com

查看更多網站流量與參與度資訊

Sumitomo Dainippon Pharma Oncology的熱門網域總造訪量

了解Sumitomo Dainippon Pharma Oncology市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

無可顯示數據

Sumitomo Dainippon Pharma Oncology的熱門網域平均造訪時長

分析Sumitomo Dainippon Pharma Oncology參與度指標。

過去 3 個月平均造訪時長

無可顯示數據

Sumitomo Dainippon Pharma Oncology的熱門網域平均頁面瀏覽量

了解Sumitomo Dainippon Pharma Oncology如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

無可顯示數據

Sumitomo Dainippon Pharma Oncology按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術Sumitomo Dainippon Pharma Oncology

这些是Sumitomo Dainippon Pharma Oncology顶级域名使用的行业网站技术

付費廣告 (2)

DoubleClick

小工具 (2)

reCAPTCHA

音訊視訊媒體 (1)

YouTube

企業解決方案 (1)

DocuSign

更多技術

7

檢視所有

新聞與訊號來自Sumitomo Dainippon Pharma Oncology

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Sumitomo Dainippon Pharma Oncology, Inc. hired Jatin J. Shah as Executive Vice President, Chief Medical Officer and Global Head of Development on Feb 22nd '22.Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage pharmaceutical company focused on research and development for novel cancer therapeutics, today announced the appointment of Jatin J. Shah, M.D. as Executive Vice President, Chief Medical Officer and Global Head of Development.

新聞Sumitomo Dainippon Pharma Oncology, Inc. launched Phase 3 WIZARD 201G study on Dec 15th '21.Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage biopharmaceutical company focused on research and development for novel cancer therapeutics, today announced that the Phase 3 WIZARD 201G study will terminate following its second interim analysis after determining there is a low probability of meeting the primary endpoint of overall survival at the final analysis.

新聞Sumitomo Dainippon Pharma Oncology, Inc. launches CanStem303C study.Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the CanStem303C study evaluating the efficacy and safety of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with previously treated metastatic colorectal cancer failed to reach the primary endpoints of overall survival (OS).